IBA Acquires ORA to Strengthen Nuclear Medicine Leadership
Louvain-La-Neuve, Belgium, December 19, 2025 — IBA (Ion Beam Applications S.A.), a global leader in particle accelerator technology and...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Louvain-La-Neuve, Belgium, December 19, 2025 — IBA (Ion Beam Applications S.A.), a global leader in particle accelerator technology and...
Los Angeles, California – November 3, 2025 NeuroSigma, Inc., a Los Angeles-based bioelectronics company, has announced a groundbreaking publication...
